📌 Key Takeaways
- Topic: Silica Microspheres: Sizes, Properties and Applications in Coatings, Cosmetics and Chromatography
- Keywords: Denka spherical silica
- Published: 2026-11-20 00:50:33
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is Diatomite? Properties, Filtration Uses and Industrial Applications
- Silica Mesh Size Chart: Mesh to Micron Conversion and How to Choose
- Buying Silica on Alibaba: How to Verify Suppliers and Avoid Common Risks
- Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
- What Is Silicon Dioxide (SiO₂)? Structure, Properties, Types and Uses Explained
- The skin is our largest organ, which consists of three layers: the epidermis, dermis, and hypodermis. Owing to its big surface zone, it also serves as an essential gateway for drug administration [ 25 ], which is fitting for both local (dermal) or systemic (transdermal) therapy [ 25, 56 ]. In spite of the popularity of this administration route, it is a challenge to get the API into deeper layers of the skin. The outermost layer of the epidermis, the stratum corneum, is the biggest hurdle to molecular penetration [ 25, 56 ]. However, the molecules must be absorbed through the capillaries of the dermis to achieve a systemic impact, which can be facilitated employing nanocarriers [ 56 ]. In addition, sweat glands or hair follicles can be effective alternative routes for the molecules to enter the deeper layers of the skin [ 25, 56 ]. In summary, it can be called as the transappendageal route. Among physicochemical properties, particle size is one of the most vital factors influencing absorption. Particles in the range between 200 and 300 nm are suitable for local treatment of the skin in diseases such as atopic dermatitis [ 25 ] since particles larger than 75 nm do not pass through the stratum corneum [ 25 ]. Smaller particles (approximately 50 nm) are suitable for systemic treatment [ 25 ], and on the whole, it can be said that nanoparticles with a diameter smaller than 25 nm can penetrate the skin most effectively, so they can be used for transdermal drug administration with an appropriate formulation [ 56 ]. By controlling the size of the nanocarrier, they penetrate to different depths in the skin. From the element of surface characteristics, cationic amino-functionalized MSNs show more efficient penetration into deeper layers of the skin than the particles with anionic surfaces of the same size [ 25 ]. The use of MSNs as a drug carrier may improve aqueous solubility, stability, and skin penetration of the drug [ 61 ]. In a research, gels containing MSN were prepared by employing distilled water to form the base, adding the gelling agent (Poloxamer 407), and adding HPMC to enhance the viscosity [ 83 ]. In another publication, MSN containing oleogels were prepared with sunflower oil and the addition of colloidal silicon dioxide as a gelling agent [ 61 ]. According to in vitro experiments, the gel matrix also affected the drug release kinetics [ 61, 83 ]. Slower drug release was observed in the case of gels containing loaded MSNs, compared to the free carriers, and the outcomes demonstrated close to zero-order release kinetics [ 61 ]. According to in vitro biocompatibility studies, this gel complex did not show any evidence of cytotoxicity on dermal fibroblast cells. Moreover, according to in vivo dermal safety studies, it has been proven that this preparation does not cause skin irritation during application, and so this formulation can be considered a safe product [ 61 ].
- Silica for Sealants: Grades, Functions and Formulation Guide
Precipitated Silica Manufacturer: Production Process and Supplier Selection Guide
What is silica (SiO₂)?
cosmetic grade silica Wet granulation is the most frequently used technique to process MSNs, because of the many possibilities inherent in it [ 106 ]. Conventional wet granulation is well-suited for the granulation of silica nanocarriers, but several things should be considered during implementation. There are two possible sequences: first, the drug loading, followed by the granulation of the loaded carriers [ 104 ], or the opposite way, the granulation of the empty carriers, then loading the drug into the prepared granules. In the first case, during the planning and implementation of the process, special attention must be paid to the critical process parameters to steer clear of premature drug release [ 104 ]. In general, it can be noted that as little moisture as possible should be used during granulation, consequently decreasing the risk of premature drug release. Still, simultaneously, moisture adequate to produce the desired agglomeration must be made sure [ 104 ]. The risk of premature drug release depends to a certain extent on the chemical structure of the API and the carrier. Szewczyk and Prokopowicz developed doxycycline-loaded MSN pellets with prolonged release kinetics [ 40 ]. First, the drug was loaded into the pores, and then pellets were produced from the loaded mesoporous material with other excipients by wet extrusion and spheronization. For comparison, traditional doxycycline pellets were also prepared. This study demonstrated the importance of utilizing mesoporous carriers for the delayed or sustained release of water-soluble drugs. Pelletization was a successful method to reduce the initial burst release of doxycycline; twice the release time was observed compared to traditional pellets [ 40 ]. Szewczyk et al. developed another DDS loaded with an antibiotic compound (cefazolin) for the treatment of osteomyelitis [ 66 ]. The amine-functionalized MSN was successfully loaded with the drug, and because of the powerful interactions between the negatively charged cefazolin and the positively charged surface of the carrier, a prolonged release of 5 days was observed, which made sure a longer antibacterial influence than with classic pellets. This was proven by the microbiological activity assays of the pellets against S. aureus culture [ 66 ]. These results are promising in antibiotic or anticancer therapy, where therapeutic concentration is needed for a longer period [ 40, 66 ]. A comparable outcome was presented in another publication about metformin-containing MSN pellets with prolonged release kinetics [ 85 ]. After drug loading, pellets were formed with the mixture of the preloaded carriers and chitosan solution, and then the pellets were coated with five layers of chitosan. Since the stomach is not considered the best possible absorption surface for metformin, it is advisable to delay the release until conditions in the intestines are ideal for maximum bioavailability. Chitosan plays an important role in this formulation; it slows down and delays the metformin release and offers delayed and prolonged release kinetics, thereby preventing speedy blood level peaks after application [ 85 ]. On the contrary, Wang et al. published a post on MSN pellets filled with poorly water-soluble carbamazepine, and they observed better oral bioavailability compared to commercially available tablets based on in vivo analysis performed on dogs [ 86 ]. In vitro dissolution studies confirmed a raised dissolution rate compared to crystalline carbamazepine due to the amorphous state of the drug within the pores. This immediate-release pellet formulation allows for a reduction in the drug dose, sustaining the same clinical influence [ 86 ].
What is the difference between fumed silica and precipitated silica?
cristobalite Flórián Benkő
What drives silica raw material prices?
what is silicon dioxide 4. Pednekar P.P., Godiyal S.C., Jadhav K.R., Kadam V.J. Nanostructures for Cancer Therapy. Elsevier; Amsterdam, The Netherlands: 2017. Chapter 23 - Mesoporous silica nanoparticles: A promising multifunctional drug delivery system. [ DOI ] [ Google Scholar ]
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.